Curaleaf: Analysts Anticipate Q1 Revenues to Hit US$254 Million
Curaleaf Holdings (CSE: CURA) is expected to release their first quarter financial results after the close of markets today. Analysts have a consensus C$27.86 12-month price target on the company, via a total of 15 analysts, with four analysts having a strong buy rating and the other 11 have buy ratings. The street high comes from BTIG with a C$34 price target, and the lowest target comes from Cormark Securities with a C$24 price target.
Fourteen analysts have revenue estimates for the first quarter. The mean between all 14 is U$254.09 million; this number has been revised downwards from U$267.07 million at the start of the year. The highest revenue estimate U$263.80, while the lowest comes from MKM Partners with a U$251 million estimate.
Eleven analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 50.25%, with this number staying flat year to date. Street high goes to BTIG with a 54.80% estimate and the lowest sits at 40% from Ladenburg Thalmann.
Onto EBITDA estimates, there are currently 13 analysts who have first quarter EBITDA estimates. The mean is currently U$60.24 million, with this number being revised downwards from U$69.15 million at the start of the year. Street high goes to Cantor Fitzgerald with a U$65.60 million EBITDA estimate and the lowest being from BTIG with a U$53.90 million estimate.
Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
